Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies
Joint Authors
Todenhöfer, Tilman
Rachner, Tilman D.
Hofbauer, Lorenz C.
Stenzl, Arnulf
Source
International Journal of Endocrinology
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-01-31
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Maintaining bone health remains a clinical challenge in patients with prostate cancer (PC) who are at risk of developing metastatic bone disease and increased bone loss due to hormone ablation therapy.
In patients with cancer-treatment induced bone loss (CTIBL), antiresorptive agents have been shown to improve bone mineral density (BMD) and to reduce the risk of fractures.
For patients with bone metastases, both zoledronic acid and denosumab delay skeletal related events (SREs) in the castration resistant stage of disease.
Novel agents targeting the Wnt inhibitors dickkopf-1 and sclerostin are currently under investigation for the treatment of osteoporosis and malignant bone disease.
New antineoplastic drugs such as abiraterone, enzalutamide, and Radium-223 are capable of further delaying SREs in patients with advanced PC.
The benefit of antiresorptive treatment for patients with castration sensitive PC appears to be limited.
Recent trials on the use of zoledronic acid for the prevention of bone metastases failed to be successful, whereas denosumab delayed the occurrence of bone metastases by a median of 4.1 months.
Currently, the use of antiresorptive drugs to prevent bone metastases still remains a field of controversies and further trials are needed to identify patient subgroups that may profit from early therapy.
American Psychological Association (APA)
Todenhöfer, Tilman& Stenzl, Arnulf& Hofbauer, Lorenz C.& Rachner, Tilman D.. 2015. Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. International Journal of Endocrinology،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1065828
Modern Language Association (MLA)
Todenhöfer, Tilman…[et al.]. Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. International Journal of Endocrinology No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1065828
American Medical Association (AMA)
Todenhöfer, Tilman& Stenzl, Arnulf& Hofbauer, Lorenz C.& Rachner, Tilman D.. Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. International Journal of Endocrinology. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1065828
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1065828